Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights

Iain C. MacDougall; Simon D. Roger; Angel De Francisco; David J.A. Goldsmith; Huub Schellekens; Hans Ebbers; Wolfgang Jelkmann; Gérard London; Nicole Casadevall; Walter H. Hörl; David M. Kemeny; Carol Pollock

doi:10.1038/ki.2011.500

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights

Iain C. MacDougall^*, Simon D. Roger, Angel De Francisco, David J.A. Goldsmith, Huub Schellekens, Hans Ebbers, Wolfgang Jelkmann, Gérard London, Nicole Casadevall, Walter H. Hörl, David M. Kemeny, Carol Pollock

^*Corresponding author for this work

Institute of Physiology

103 Citations (Scopus)

Abstract

Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

Original language	English
Journal	Kidney International
Volume	81
Issue number	8
Pages (from-to)	727-732
Number of pages	6
ISSN	0085-2538
DOIs	https://doi.org/10.1038/ki.2011.500
Publication status	Published - 02.04.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Access to Document

10.1038/ki.2011.500

Cite this

MacDougall, I. C., Roger, S. D., De Francisco, A., Goldsmith, D. J. A., Schellekens, H., Ebbers, H., Jelkmann, W., London, G., Casadevall, N., Hörl, W. H., Kemeny, D. M., & Pollock, C. (2012). Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights. Kidney International, 81(8), 727-732. https://doi.org/10.1038/ki.2011.500

@article{c4cf2afc334149ce8b1030bb7dcd8fc4,

title = "Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights",

abstract = "Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.",

author = "MacDougall, \{Iain C.\} and Roger, \{Simon D.\} and \{De Francisco\}, Angel and Goldsmith, \{David J.A.\} and Huub Schellekens and Hans Ebbers and Wolfgang Jelkmann and G{\'e}rard London and Nicole Casadevall and H{\"o}rl, \{Walter H.\} and Kemeny, \{David M.\} and Carol Pollock",

year = "2012",

month = apr,

day = "2",

doi = "10.1038/ki.2011.500",

language = "English",

volume = "81",

pages = "727--732",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "8",

}

MacDougall, IC, Roger, SD, De Francisco, A, Goldsmith, DJA, Schellekens, H, Ebbers, H, Jelkmann, W, London, G, Casadevall, N, Hörl, WH, Kemeny, DM & Pollock, C 2012, 'Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights', Kidney International, vol. 81, no. 8, pp. 727-732. https://doi.org/10.1038/ki.2011.500

TY - JOUR

T1 - Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights

AU - MacDougall, Iain C.

AU - Roger, Simon D.

AU - De Francisco, Angel

AU - Goldsmith, David J.A.

AU - Schellekens, Huub

AU - Ebbers, Hans

AU - Jelkmann, Wolfgang

AU - London, Gérard

AU - Casadevall, Nicole

AU - Hörl, Walter H.

AU - Kemeny, David M.

AU - Pollock, Carol

PY - 2012/4/2

Y1 - 2012/4/2

N2 - Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

AB - Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

UR - https://www.scopus.com/pages/publications/84859424243

U2 - 10.1038/ki.2011.500

DO - 10.1038/ki.2011.500

M3 - Short survey

AN - SCOPUS:84859424243

SN - 0085-2538

VL - 81

SP - 727

EP - 732

JO - Kidney International

JF - Kidney International

IS - 8

ER -

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this